Feladilimab is under clinical development by GSK and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Feladilimab’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 03 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 03 Oct 2022 increased Feladilimab’s LoA and PTSR for Squamous Non-Small Cell Lung Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Feladilimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Feladilimab overview

GSK-3359609 is under development for the treatment of advanced solid tumors including non-small cell lung cancer, squamous non-small cell lung cancer, bladder cancer, cervical cancer, esophageal, urothelial cancer, clear renal cell carcinoma, head and neck cancer squamous cell carcinoma including oral, pharyngeal and larynx cancer, hypopharyngeal cancer, paranasal sinus and nasal cavity cancer, malignant pleural mesothelioma, squamous and cutaneous melanoma, prostate cancer, castration resistant prostate cancer, metastatic colorectal cancer and recurrent head and neck cancer squamous cell carcinoma, oral cavity (Mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, HPV associated cancer. It is administered intravenously as an infusion. It acts by targeting inducible T-Cell costimulator, ICOS

The drug candidate was also under development for the treatment for squamous cell carcinoma, non-small cell lung cancer, multiple myeloma, squamous non-small cell lung cancer (third line) and non-squamous non-small cell lung cancer.

GSK overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

Quick View Feladilimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Feladilimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: GSK
  • Originator: Inserm Transfert and GSK
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.